BACKGROUND: Major salivary gland cancers (M-SGCs) are rare, and have distinct heterogeneous histopathological subtypes. To the authors' knowledge, no consistent evidence of an association between cigarette smoking and the risk of M-SGCs has appeared to date. Furthermore, evidence of potential heterogeneity in the impact of smoking on histopathological subtypes is scarce, despite the fact that the histopathological subtypes of M-SGC exhibit different genetic features. METHODS: The authors conducted a casecontrol study to investigate the association between smoking and M-SGC by histopathological subtype. Cases were 81 patients with M-SGCs and the controls were 810 age-matched and sex-matched first-visit outpatients without cancer treated at Aichi Cancer Center Hospital from 1988 to 2005. Odds ratios (OR) and 95% confidence intervals (95% CI) were assessed by conditional logistic regression analysis with adjustment for potential confounders. RESULTS: Smoking was found to be associated with a significantly increased risk of M-SGC overall, with an OR of 3.45 (95% CI, 1.58-7.51; P 5.001) for heavy smokers compared with never-smokers. A significant dose-response relationship was observed (P for trend, .001). When stratified by histological subtype, no obvious impact of smoking was observed among patients with mucoepidermoid carcinoma (MEC). In contrast, smoking demonstrated a significantly increased risk of M-SGCs other than MEC, with an OR of 5.15 (95% CI, 2.06-12.87; P<.001) for heavy smokers compared with never-smokers. The authors observed possible heterogeneity with regard to the impact of smoking on risk between MEC and M-SGCs other than MEC (P for heterogeneity, .052). CONCLUSIONS: The results of the current study demonstrate a significant positive association between cigarette smoking and the risk of M-SGC overall. However, the impact of smoking appeared to be limited to M-SGCs other than MEC. Cancer 2018;124:118-24.
INTRODUCTION
Major salivary gland cancer (M-SGC) is relatively rare, accounting for 1% to 6% of all head and neck cancers and 0.3% of all human cancers.
1 Primary M-SGC comprises a heterogeneous group of cancers in terms of histological and clinical behavior. According to the 2017 World Health Organization (WHO) classification of tumors, M-SGC is classified into 20 different histopathologic subtypes, 2 among which mucoepidermoid carcinoma (MEC; approximately 35%) is most common, followed by adenoid cystic carcinoma (AdCC; approximately 19%) and adenocarcinoma (ADCA; approximately 12%). [3] [4] [5] [6] Although to the best of our knowledge no one predominant factor has been associated conclusively with the development of M-SGC, several factors have been implicated as potential causes, including exposure to ionizing radiation, [7] [8] [9] [10] especially radiotherapy [11] [12] [13] [14] ; industrial exposure among hair dressers 14, 15 and in rubber manufacturing 16 ; and diagnosis of a previous cancer. 14, 17 Although smoking is a strong carcinogen in many cancers, to the best of our knowledge few studies to date have examined the effect of smoking on the risk of M-SGC, and the 7 studies we are aware of have reported inconsistent results, [14] [15] [16] [18] [19] [20] [21] with 4 indicating a positive association 15, 16, 18, 20 and the remainder demonstrating no appreciable association. 14, 19, 21 In addition, these studies did not consider potential heterogeneity in the impact of smoking on risk by histopathological subtype of M-SGC. A recent study demonstrated that M-SGCs have heterogeneous genetic features according to histopathologic subtype. For example, molecular cytogenetic analyses have identified recurring translocations as a key genomic event in MEC (mucoepidermoid carcinoma translocated 1 [MECT1]-mastermindlike gene family [MAML2] ) and AdCC (MYB-NF1B). [22] [23] [24] [25] Conversely, the most recent comprehensive genomic profiling of M-SGC indicated that ADCA and salivary duct carcinoma (SDC) have diverse genomic mutations but not specific translocations. 26 Therefore, we hypothesized that the influence of smoking on the risk of M-SGC also may differ by histological subtype.
Herein, we conducted a case-control study to evaluate the impact of smoking on the risk of M-SGC overall and the heterogeneity of the impact by histopathologic subtype in a Japanese population.
MATERIALS AND METHODS

Objectives
The subjects were selected from the database of the first and second versions of the Hospital-based Epidemiologic Research Program of Aichi Cancer Center (HERPACC) (version 1 was from 1988-2000 and version 2 was from 2001-2005.) Details regarding the framework have been described elsewhere. 27, 28 In brief, all outpatients on their first visit to Aichi Cancer Center Hospital (ACCH) were requested to provide demographic information, including that regarding lifestyle, before their symptoms developed. Responses were collected systematically and checked by trained interviewers. Data were loaded into the HER-PACC database and periodically linked with the hospital cancer registry system to update cancer incidence and vital status. All participants provided written informed consent to participate.
From the patients enrolled, 11 patients were excluded: 7 because their pathological diagnosis could not be confirmed and 4 because of a previous diagnosis of cancer. Finally, the case participants totaled 81 patients, consisting of 53 patients from HERPACC version 1 and 28 from version 2, who had no history of cancer and had been pathologically diagnosed with M-SGC at ACCH. The control subjects were 810 first-visit outpatients during the same period who were confirmed not to have cancer and no history of prior cancer. Noncancer status was confirmed by medical examination. Controls were selected randomly and matched individually by age (63 years) and sex (male and female), with a case:control ratio of 1:10. This matching ratio of 1:10 aimed to maintain subject numbers in stratified analysis in conditional logistic regression analyses.
The current study was approved by the Institutional Ethics Committee at ACCH.
Assessment of Histopathological Diagnoses
Histopathological diagnoses of M-SGC using hematoxylin and eosin staining and immunohistopathological staining were made by pathologists at ACCH. Histopathological subtypes were defined in accordance with the 1991 edition of the WHO classification, 29 which classifies M-SGC into 18 histologic subtypes. In the current study, cases were divided into 4 groups according to prevalence, namely the 3 most common (ADCA, MEC, and AdCC) and all others, including those with miscellaneous histology.
Information Regarding Smoking and Other Lifestyle Factors
Environmental factors including smoking and drinking were obtained from a self-administered questionnaire. Information regarding smoking status was obtained in the 3 categories of nonsmoker, former smoker, and current smoker, with former smokers defined as those who had quit smoking >1 year previously. Cumulative smoking was evaluated as pack-years (PY), the product of the number of packs of cigarettes smoked per day and the number of years of smoking. In the current study, subjects were divided into 3 categories of nonsmoker, moderate smoker (<30 PY), and heavy smoker (30 PY).
Drinking status was divided into 3 categories of never, former, and current. Former drinkers were defined as those who had quit drinking for >1 year. Alcohol consumption of each beverage type (Japanese sake, beer, shochu, whiskey, and wine) was estimated as the average number of drinks per day, which was converted into ethanol equivalents. We divided subjects into the 3 categories of nondrinkers, moderate drinkers (<10 g ethanol/day), and heavy drinkers (10 g ethanol/day). We considered occupation as an indicator of individual socioeconomic status.
Statistical Analysis
To assess the association between smoking and M-SGC, we applied odds ratios (ORs) and 95% confidence intervals (95% CIs) estimated by conditional logistic regression models. We evaluated the impact of smoking in 2 multivariate models: model 1 consisted of age and study group (HERPACC 1 and 2), whereas model 2 consisted of the factors in model 1 as well as drinking status (neverdrinker, ever-drinker, and current drinker) and occupation (white collar, blue collar, and other workers). Trend analysis of smoking was evaluated using the scores of 0 indicating a never-smoker, 1 indicating a moderate smoker, and 2 indicating a heavy smoker. Interaction between smoking and histopathology was assessed with a model that included the interaction term for the combination of cumulative smoking as a continuous variable and histopathology (MEC vs M-SGCs other than MEC). All analyses were performed using Stata SE statistical software (version 13.1; StataCorp LLC, College Station, Texas). Two-sided P values <.05 were considered to indicate statistical significance.
RESULTS
Baseline demographic characteristics of the cases and controls are shown in Table 1 . Age and sex were appropriately matched. With regard to alcohol drinking status, there was no obvious difference between cases and controls, whereas for alcohol consumption, heavy drinkers were more prevalent among cases, as were blue collar workers. Distribution of the primary subsite and histopathological subtype among the cases is shown at the bottom of Table  1 . The parotid gland was the most frequent primary subsite. By histopathological subtype, AdCC, ADCA, MEC, and others comprised 14 (17.3%), 18 (22.2%), 15 (18.5%), and 34 (42.0%) cases, respectively. Of the others, squamous cell carcinoma and carcinoma in pleomorphic adenoma were the most frequent. Table 3 shows the risk of cumulative smoking on M-SGC according to histopathological subtype. With regard to AdCC, ADCA, and others, positive associations with smoking were observed. Specifically for ADCA and others, heavy smokers demonstrated significantly higher risk compared with nonsmokers, and a significant doseresponse relationship was observed (P for trend of .008 for ADCA and .033 for others). Although not significant, the ORs for smoking among patients with AdCC were above unity. In contrast, no obvious association was observed for MEC, with ORs of 0.78 (95% CI, 0.17-3.50) for moderate smokers and 0.65 (95% CI, 0.11-3.91) for heavy smokers (Table 3) . We analyzed contrasting histopathological subtypes, namely MEC versus M-SGCs other than MEC (lower section of Table 3 ). Among patients with M-SGCs other than MEC, heavy smoking was found to be positively associated with risk compared with nonsmokers, with an OR of 5.15 (95% CI, 2.06-12.87) and demonstrating a significant dose-response relationship (P for trend, <.001). We observed possible heterogeneity between MEC and M-SGCs other than MEC in terms of smoking (P for heterogeneity, .052). The impact of smoking on M-SGCs other than MEC was observed consistently after stratification by subsite region (parotid gland and submandibular gland), patient sex, and other confounders.
Impact of Smoking on the Risk of M-SGC Overall
Impact of Alcohol Consumption
Supporting Information Table 1 shows the association between alcohol drinking and risk of M-SGC overall. With regard to drinking status, former and current drinking demonstrated no apparent association with the risk of M-SGC. With regard to alcohol consumption, an association was not evident after adjustment for smoking and socioeconomic status.
DISCUSSION
In the current study, we found a significant association between M-SGC overall and smoking after consideration of potential confounders, including drinking and socioeconomic status. Moreover, the impact of smoking on MSGCs was suggestive of being heterogeneous according to histopathological subtype. With regard to MEC, the impact of smoking was not obvious, whereas the impact on M-SGCs other than MEC was significant. To our knowledge, 7 epidemiologic studies to date have evaluated the association between smoking and the risk of M-SCG overall, [14] [15] [16] [18] [19] [20] [21] but the direction of impact was not consistent. Four of these studies indicated that smoking was a risk factor for M-SCG. 15, 16, 18, 20 For example, in their population-based case-control study, Hayes at el reported that being an ever-smoker was significantly associated with the risk of M-SGC compared with being a nonsmoker, with ORs of 9.0 for men and 3.8 for women. 18 Similarly, and consistent with the findings of the current study, the other 3 studies demonstrated a positive association between smoking and M-SCG. 15, 16, 20 In contrast, the other 3 case-control studies did not indicate a positive association between smoking and M-SGC. 14, 19, 21 One possible reason for this inconsistency might be selection bias. The control subjects in the latter 3 case-control studies without a positive association 14, 19, 21 mainly were patients with other cancers, which therefore led to a more conservative association between smoking and risk. Another possibility for the lack of an association might be the higher prevalence of MEC (mostly 20%-30%) among cases. Histological distribution in the current study was in keeping with that in a Japanese population, 30 although it differed from that in the United States 3 and Europe. 6, 31 MEC was found to be more prevalent in the United States, 3 and AdCC was more prevalent in Europe. 6, 31 Taken together, it might be that the higher prevalence of MEC reduced the apparent risk of smoking on M-SGCs overall in Western countries, leading to the inconsistency noted with regard to the risk of smoking in past reports. [14] [15] [16] [18] [19] [20] [21] This lack of an association with smoking in patients with MEC is described below.
It is interesting to note that the findings of the current study indicated that the impact of smoking is heterogeneous among histological subtypes. Smoking increased the risk of M-SGCs other than MEC, for which it had negligible impact. Although to the best of our knowledge the mechanism behind this heterogeneous impact remains unclear, the current study results may suggest that smoking impacts different molecular features among types of M-SGC. With regard to MEC, recent studies have demonstrated that a key oncogenic event of MEC is the chromosomal translocation of MECT1/ 3-MAML2.
23,25,32
Kang et al evaluated 18 patients with primary MEC by whole-exome sequencing. 22 In their analysis, although 80% of patients with MEC had the MECT1-MAML2 translocation, only 30% were ever-smokers. 22 Given this, smoking might not be associated with this pivotal oncogenic translocation in MEC, and factors other than smoking might play a role in MEC carcinogenesis.
A recent genomic profiling of 149 patients with ADCA, carcinoma in pleomorphic adenoma, and SDC by Wang et al indicated that although ADCA and SDC have diverse genomic alterations, they lack a specific translocation such as the MECT1-MAML2 in MEC. 26 They identified frequent alterations in key cancer genes and pathways, such as TP53, ERBB2, and PIK3CA. 26 Previous studies reported that smoking was associated with increased mutation burdens of multiple distinct mutational signatures. [33] [34] [35] [36] [37] Significantly positive associations between smoking and M-SGCs other than MEC might indicate that smoking induces nonspecific and variable genetic alterations, leading to carcinogenesis of ADCA and SDC.
With respect to AdCC, the results of the current study demonstrated an increasing risk in smokers compared with never-smokers, although the impact was marginal. AdCC is characterized by oncogenic driver translocation, 38, 39 as well as several genomic mutations in key cancer genes and pathways, 4,40 Therefore, we speculated that the genomic mutation induced by smoking might have a partial impact on the cancerization of AdCC. At any rate, future studies regarding the impact on environmental factors by the genomic profile of cancers may shed light on how environment plays a role in the heterogeneous evolution of cancer.
The current study had several methodological strengths. First, the minimally biased collection of environmental information should be noted. In the HER-PACC studies, subjects completed self-administered questionnaires before diagnosis, which may have minimized the recall bias that is inherent in case-control studies. Second, we selected control subjects from among patients who were confirmed to have no cancer at the same hospital they are expected to visit if they subsequently do develop cancer. This means that controls were selected from the population from which the cases arose, warranting the internal validity of the current study. The current study also has several potential limitations. First, the sample size of patients with M-SGC was limited, and statistical power therefore might be insufficient. Second, the external validity was limited by the selection of controls from the hospital patient population. To evaluate this possibility, we previously confirmed that our control populations have characteristics similar to those of the general population with respect to exposures of interest, in this case smoking. 41 Finally, pathological diagnosis in the current study was performed based on the 1991 WHO classification, 29 despite the fact that the most recent 2017 WHO classification currently is available. 2 However, the impact of the use of the 1991 classification on the current study results likely was limited because the definitions of AdCC, MEC, and ADCA (shown as adenocarcinoma, not otherwise specified in the 2017 WHO classification) have not changed markedly.
The results of the current study demonstrate that smoking influenced the risk of M-SGC overall. Furthermore, the impact of smoking was found to be heterogeneous by histopathological subtype. No clear association was observed in MEC; however, significant positive associations were noted in M-SGCs other than MEC. Replication of these findings in larger studies is warranted. 
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